D I Brixner

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. doi Evaluation of cardiovascular risk factors, events, and costs across four BMI categories
    D I Brixner
    Department of Pharmacotherapy, University of Utah, 30 South 2000 East, Room 4781, Salt Lake City, UT 84112, USA
    Obesity (Silver Spring) 21:1284-92. 2013
  2. ncbi Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations
    Diana I Brixner
    University of Utah College of Pharmacy, Salt Lake City, UT 84112, USA
    Curr Med Res Opin 24:2597-607. 2008
  3. doi Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
    D I Brixner
    University of Utah, Pharmacotherapy Outcomes Research Center, Salt Lake City, UT 84112, USA
    Diabetes Obes Metab 11:1122-30. 2009
  4. doi Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
    Diana I Brixner
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Am J Health Syst Pharm 66:2171-8. 2009
  5. doi Assessment of time to follow-up visits in newly-treated hypertensive patients using an electronic medical record database
    Diana I Brixner
    University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT 84112, USA
    Curr Med Res Opin 26:1881-91. 2010
  6. ncbi All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation
    Sameer R Ghate
    Pharmacotherapy Outcomes ResearchCenter, University of Utah, 30 South 2000 East, RM 258, Salt Lake City, UT 84112 5820, USA
    J Manag Care Pharm 17:672-84. 2011
  7. ncbi The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations
    D I Brixner
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA
    Curr Med Res Opin 23:2887-95. 2007
  8. ncbi Physician utilization by insurance type among youth with type 2 diabetes
    Carrie McAdam-Marx
    Department of Pharmacotherapy, University of Utah, 421 Wakara Way, Rm 208, Salt Lake City, UT 84108, USA
    Am J Manag Care 16:55-64. 2010
  9. doi Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data
    Joanne LaFleur
    Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA
    J Bone Miner Metab 29:193-200. 2011
  10. doi Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin
    Carrie McAdam-Marx
    University of Utah Department of Pharmacotherapy, Salt Lake City, Utah 84108, USA
    Curr Med Res Opin 26:191-201. 2010

Detail Information

Publications28

  1. doi Evaluation of cardiovascular risk factors, events, and costs across four BMI categories
    D I Brixner
    Department of Pharmacotherapy, University of Utah, 30 South 2000 East, Room 4781, Salt Lake City, UT 84112, USA
    Obesity (Silver Spring) 21:1284-92. 2013
    ..The purpose of this study was to analyze the 1-year cost of cardiovascular (CV) events by body mass index (BMI) subgroups from a US employer health plan perspective...
  2. ncbi Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations
    Diana I Brixner
    University of Utah College of Pharmacy, Salt Lake City, UT 84112, USA
    Curr Med Res Opin 24:2597-607. 2008
    ....
  3. doi Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
    D I Brixner
    University of Utah, Pharmacotherapy Outcomes Research Center, Salt Lake City, UT 84112, USA
    Diabetes Obes Metab 11:1122-30. 2009
    ..This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting...
  4. doi Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
    Diana I Brixner
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Am J Health Syst Pharm 66:2171-8. 2009
    ..Treatment persistence and cost of therapy for patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a plus ribavirin and peginterferon alfa-2b plus ribavirin were evaluated...
  5. doi Assessment of time to follow-up visits in newly-treated hypertensive patients using an electronic medical record database
    Diana I Brixner
    University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT 84112, USA
    Curr Med Res Opin 26:1881-91. 2010
    ..Findings were compared to treatment guidelines which recommend monthly follow-up in treatment naive patients until blood pressure (BP) levels are controlled...
  6. ncbi All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation
    Sameer R Ghate
    Pharmacotherapy Outcomes ResearchCenter, University of Utah, 30 South 2000 East, RM 258, Salt Lake City, UT 84112 5820, USA
    J Manag Care Pharm 17:672-84. 2011
    ..Bleeding is a major complication of warfarin therapy. Assessing the cost of warfarin-associated bleeding may more fully describe the costs associated with warfarin use...
  7. ncbi The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations
    D I Brixner
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA
    Curr Med Res Opin 23:2887-95. 2007
    ....
  8. ncbi Physician utilization by insurance type among youth with type 2 diabetes
    Carrie McAdam-Marx
    Department of Pharmacotherapy, University of Utah, 421 Wakara Way, Rm 208, Salt Lake City, UT 84108, USA
    Am J Manag Care 16:55-64. 2010
    ....
  9. doi Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data
    Joanne LaFleur
    Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA
    J Bone Miner Metab 29:193-200. 2011
    ..3%). Despite the limitations, the EMR data were useful for identifying women at highest risk for fracture. Some evidence of bias in reporting rates was present. EMR data can be useful for identifying high fracture risk patients...
  10. doi Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin
    Carrie McAdam-Marx
    University of Utah Department of Pharmacotherapy, Salt Lake City, Utah 84108, USA
    Curr Med Res Opin 26:191-201. 2010
    ..The aim of this study was to compare the amount of insulin utilized in a large cohort of patients with type 2 diabetes treated with either DET or GLAR in the real-world setting considering the use of other antidiabetic agents...
  11. doi Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting
    Carrie McAdam-Marx
    Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, Utah 84108, USA
    Clin Ther 31:1116-23. 2009
    ..Resistant hypertension, or failure to attain blood pressure (BP) goals while treated with > or = 3 antihypertensives (including a diuretic), occurred in 15% to 18% of patients in prospective cohort trials...
  12. doi Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature
    Joanne LaFleur
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA
    Ann Pharmacother 42:375-86. 2008
    ....
  13. ncbi Antiplatelet medication management in patients hospitalized with ischemic stroke
    Nancy A Nickman
    Pharmacotherapy Outcomes Research Center, University of Utah, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA
    Am J Health Syst Pharm 64:2250-6. 2007
    ..The use of antiplatelet agents in patients hospitalized with ischemic stroke was studied...
  14. ncbi Back pain and productivity: measuring worker productivity from an employer's perspective
    Vijay N Joish
    Pharmacotherapy Outcomes Research Center, University of Utah Health Sciences, Center, USA
    J Pain Palliat Care Pharmacother 18:79-85. 2004
    ..This article examines various methods to assess productivity gains or losses, from an employer's perspective...
  15. ncbi Documentation of chemotherapy infusion preparation costs in academic- and community-based oncology practices
    Diana I Brixner
    University of Utah Pharmacotherapy Outcomes Research Center, Salt Lake City, Utah, 84108, USA
    J Natl Compr Canc Netw 4:197-208. 2006
    ..These data provide scientific support for the consideration of appropriate reimbursement for chemotherapy services provided by pharmacists to Medicare beneficiaries...
  16. ncbi Naturalistic impact of second-generation antipsychotics on weight gain
    Diana I Brixner
    Executive Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, UT 84108, USA
    Ann Pharmacother 40:626-32. 2006
    ..Body mass index (BMI) has been studied in clinical trials with limited comparison between drugs...
  17. ncbi The case against excessive cost sharing
    Diana I Brixner
    University of Utah College of Pharmacy, Salt Lake City, UT 84108, USA
    Am J Manag Care 12:S162-4; discussion S167-72; quiz S173-6. 2006
  18. ncbi Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin
    Joanne LaFleur
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, 84108, USA
    Ann Pharmacother 40:1274-9. 2006
    ..A fixed-dose combination product, extended-release niacin/lovastatin (ERNL), has been shown to be beneficial in lipid management; however, little is known regarding patient behavior with ERNL therapy...
  19. ncbi Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs
    Joseph E Biskupiak
    Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, 421 Wakara Way, Suite 208, Salt Lake City, UT 84108, USA
    J Pain Palliat Care Pharmacother 20:7-14. 2006
    ....
  20. ncbi Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism
    Freddy M Creekmore
    College of Pharmacy, University of Utah, Salt Lake City, Utah 84112
    Pharmacotherapy 26:1438-45. 2006
    ....
  21. ncbi Effects of benefit design change across 5 disease states
    Diana I Brixner
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA
    Am J Manag Care 13:370-6. 2007
    ..To assess the effects of benefit design change (BDC) on medication adherence and persistence (including switch in therapy), drug costs, and total healthcare costs...
  22. ncbi The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database
    Vijay N Joish
    Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT, USA
    Curr Med Res Opin 21:535-44. 2005
    ....
  23. ncbi Cost-effectiveness of insulin analogs
    Diana I Brixner
    Outcomes Research Center, University of Utah, Salt Lake City, UT 84108, USA
    Am J Manag Care 14:766-75. 2008
    ..To examine the cost-effectiveness of analogs versus human insulins, citing primarily studies conducted in the United States...
  24. ncbi Prevalence and burden of migraine and the impact on managed care
    Diana I Brixner
    Department of Pharmacotherapy, University of Utah, Salt Lake City, USA
    Manag Care 16:2-3; discussion 15-7. 2007
  25. ncbi Opioid expenditures and utilization in the Medicaid system
    Diana I Brixner
    Department of Pharmacotheraphy, University of Utah, Salt Lake City, UT 84112, USA
    J Pain Palliat Care Pharmacother 20:5-13. 2006
    ..By 2003, opioids represented about a four percent share of all Medicaid prescription drugs. Variations among the states in per-enrollee spending on opioids are substantial. The appropriateness of these variations is unknown...
  26. doi Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application
    Junhua Yu
    University of Utah Pharmacotherapy Outcomes Research Center, Salt Lake City, 84112, USA
    CNS Drugs 24:695-712. 2010
    ..There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects...
  27. ncbi Clinical and economic outcomes in the treatment of lower respiratory tract infections
    Diana I Brixner
    Department of Pharmacy Practice, University of Utah, Salt Lake City, USA
    Am J Manag Care 10:S400-7. 2004
  28. ncbi Improving acute otitis media outcomes through proper antibiotic use and adherence
    Diana I Brixner
    Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, Salt Lake City, UT, USA
    Am J Manag Care 11:S202-10. 2005
    ..As such, managed care organizations should consider strategies for achieving better patient adherence with antibiotic regimens for AOM...